Welcome to our dedicated page for Pavmed SEC filings (Ticker: PAVM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
PAVmed Inc. SEC filings document its medical technology business, subsidiary operations and capital structure. Form 8-K reports cover operating results, business updates, Regulation FD disclosures, material agreements and Nasdaq listing-compliance matters for the company and its medical device, diagnostics and digital health activities.
Proxy statements and stockholder-meeting filings describe governance, voting matters and authorization of share issuances tied to preferred stock, warrants and convertible debt. Recent capital-structure disclosures include Series D Convertible Preferred Stock, warrants to purchase preferred stock, redemption of Series C Preferred Stock, and refinancing of a senior secured convertible note.
PAVmed Inc. Schedule 13G/A reports that Tasso Partners, LLC beneficially owns 912,996 shares (14.3%) and that Dana Carrera beneficially owns 974,246 shares (15.3%). The filing ties the ownership percentages to 6,383,089 shares outstanding as of March 27, 2026 and discloses related convertible warrants and managerial control relationships.
Lee Victoria Tou-ho reported acquisition or exercise transactions in this Form 4 filing.
PAVmed Inc. reported that Chief Medical Officer Lee Victoria Tou-ho received a grant of 70,000 shares of common stock as an equity award. The restricted stock was granted at $0.00 per share and increases her direct holdings to 71,666 shares.
The award consists of restricted stock under PAVmed’s Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan and has a single vesting date of May 20, 2029. The shares are subject to forfeiture if the required service period is not completed, tying the grant to long-term employment and performance.
PAVmed Inc. filed an initial insider report for Chief Medical Officer Lee Victoria Tou-ho, showing ownership of 1,666 shares of Common Stock as restricted stock granted under the company’s Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan.
These restricted shares have a single vesting date of May 20, 2028 and are subject to forfeiture if the required service period is not completed, meaning the CMO must remain in service through that date to fully retain the award.
Scopia Holdings LLC and Matthew Sirovich reported beneficial ownership stakes in PAVmed Inc. Scopia Holdings LLC beneficially owns 630,118 shares of Common Stock (CUSIP 70387R502), representing 9.87%. Mr. Matthew Sirovich is reported as beneficially owning 637,670 shares, representing 9.99%, which reflects his control over the Scopia holdings plus 7,552 additional shares. The reporting address is c/o Scopia Capital Management LP, and the signature date provided is 04/13/2026.
PAVmed Inc. Chairman and CEO Lishan Aklog, M.D. filed a Schedule 13D reporting beneficial ownership of 369,068 shares of PAVmed common stock, representing 5.1% of the 7,272,739 shares outstanding as of April 2, 2026. The issuer granted him 350,000 shares of restricted common stock under its Seventh Amended and Restated Long-Term Incentive Equity Plan in consideration of services as Chairman and CEO. These restricted shares, along with existing holdings, options and small indirect interests through entities and family members, make up his reported beneficial ownership. The filing states the shares are held for investment purposes and that, apart from routine investment activity consistent with his roles, he has no current plans for major corporate changes.
PAVmed Inc. reports Schedule 13G ownership disclosures by David S. Nagelberg and the David S. Nagelberg 2003 Revocable Trust. The filing states the Trust beneficially owns 461,539 shares (7.2%) and Mr. Nagelberg beneficially owns 546,964 shares (8.6%), based on 6,383,089 shares outstanding as of March 27, 2026. The Trust holdings are controlled by Mr. Nagelberg; sole voting and dispositive power figures match the share counts. A Joint Filing Agreement is included as Exhibit 99.1.
PAVmed Inc. Schedule 13G filed by Scott V. Dols reports beneficial ownership of 346,155 shares of Common Stock, representing 5.4% of the class. The percent is calculated using 6,383,089 shares outstanding as of March 27, 2026 per the company annual report.
Tasso Partners, LLC filed an initial ownership report as a more than ten percent owner of PAVmed Inc.. The filing shows direct ownership of 912,996 shares of Common Stock. It also reports a Warrant to purchase up to 5,365 shares of Series D Preferred Stock at $1,000 per share, expiring on February 3, 2031. Each Series D Preferred share has a stated value of $1,000 and is convertible into Common Stock at a $6.50 per share conversion price, for an aggregate of up to 825,385 shares of Common Stock. The issuer may choose, upon exercise of the Warrant, to issue those Common Stock shares directly instead of issuing the preferred shares first.
Aklog Lishan reported acquisition or exercise transactions in this Form 4 filing.
PAVmed Inc. Chairman and CEO Lishan Aklog received a grant of 350,000 shares of restricted common stock, awarded at $0.00 per share as equity compensation. The restricted stock was granted under PAVmed's Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan and has a single vesting date of May 20, 2029. The award is subject to forfeiture if the required service period is not completed, tying the grant to long-term leadership retention. Following this grant, Dr. Aklog directly holds 357,614 shares of common stock, with additional indirect interests reported through family members and investment entities.
PAVmed Inc. Schedule 13G reports that the Craig Kallman 2015 Living Trust and Craig Kallman together beneficially own 384,616 shares of PAVmed common stock. The filing states this equals 6.0% of the class, based on 6,383,089 shares outstanding as of March 27, 2026.
The Trust holds sole voting and sole dispositive power over the 384,616 shares. The Reporting Persons filed a Joint Filing Agreement and note Mr. Kallman controls the Trust.